Cases Of Uveitis Research Articles

Pattern of Uveitis in Northern Vietnam

ABSTRACT Purpose To characterize the spectrum of uveitis in patients visiting three tertiary hospitals in Hanoi, Vietnam. Methods This study collected prospective and multicenter data from patients diagnosed with uveitis at three tertiary hospitals in Hanoi City, Vietnam, between January 2022 and January 2024. Data on age, sex, clinical and laboratory findings, and etiology were collected. Results Of 410 patients included, 54.6% were women. The mean age of patients was 39.9 years. Most cases were unilateral and chronic. Anterior uveitis was the most common case (40%), followed by panuveitis (30%), posterior uveitis (26.1%), and intermediate uveitis (3.9%). Undifferentiated uveitis, accounting for 32%, was the most prevalent form across all anatomical groups. The leading etiologies for anterior uveitis included Posner–Schlossman syndrome (18.5%), cytomegalovirus (CMV)-induced uveitis (11%), and Herpes simplex virus–induced uveitis (8.5%). For posterior uveitis, the primary causes were Vogt–Koyanagi–Harada (VKH) syndrome (17.8%), toxocariasis (10.3%), and toxoplasmosis (6.5%). The identified causes of panuveitis included VKH syndrome (24.4%), Behcet’s disease (15.4%), and CMV-induced panuveitis (5.7%). We observed six cases of uveitis associated with Haemophilus influenzae (1.5%) without any concomitant systemic symptoms. In our patient population, the most common complication was cataract (11.2%), followed by uveitic macular edema (11%). Conclusions Various uveitis patterns were observed among Vietnamese patients, with non-infectious uveitis being predominant.

Unilateral Exudative Retinal Detachment and Uveitis Accompanied by a Large Subretinal Deposit on the Macula Secondary to Bartonella Henselae Infection

Bartonella henselae is a Gram-negative bacillus, mainly parasitizing on cats. When a child is scratched by a cat, they may present with the disease symptoms including regional lymphadenopathy, malaise, fever, and splenomegaly, which is known as cat-scratch disease (CSD). Ocular manifestations occur in 5–10% of patients with CSD. Neuroretinitis is the most common, and, in addition, Parinaud oculoglandular syndrome, endophthalmitis, retinochoroiditis, vascular occlusions, multiple mass-like lesions resembling ocular metastases, serous macular detachments, and retinal vasoproliferative lesions may also occur. We report a case of unilateral exudative retinal detachment and uveitis with a large subretinal deposit on the macula in a 6-year-old female with CSD, along with lymphadenitis on her left thigh. To the best of our knowledge, this case of exudative retinal detachment and uveitis with a large subretinal deposit under the retina affecting the macular area above the optic disc has not been previously reported.

FIRST EXPERIENCE WITH COMBINED CYCLOPHOTOCOAGULATION TECHNIQUE USING TRANSILLUMINATION

Relevance: сurrently, micropulse transscleral cyclophotocoagulation is widely used for the treatment of refractory glaucoma. It has a high safety profile and can be applied to eyes with high visual potential. Continuous-wave cyclophotocoagulation has a more pronounced hypotensive effect; however, it is accompanied by a significant number of complications. During transscleral cyclophotocoagulation, it is suggested to use a standard position for the sensor, though the position of the ciliary processes may vary.Purpose: to analyze the effectiveness and safety of the combined cyclophotocoagulation technique using transillumination.Materials and Methods: the study included 22 patients (22 eyes) who underwent combined cyclophotocoagulation with transillumination. The observation period was 6 months, with control examinations conducted at 1, 3, and 6 months. At each visit, refractokeratometry, visual acuity assessment, ultrasound examination (B-scan), tonometry using the Maklakov method were performed. There was one case of postoperative uveitis in the form of iridocyclitisResults: after six months, intraocular pressure decreased by 45% from the baseline level-from 35.5 (34–38.5) mm Hg to 20 (20–21) mm Hg. The number of hypotensive therapy drops was also reduced-from 7 (5.75–7) to 4 (3.25–4) drops per day.Conclusion: combined cyclophotocoagulation with transscleral transillumination demonstrated a stable hypotensive effect over 6 months, with no significant complications such as prolonged hypotony, phthisis bulbi, or persistent refractory uveitis, which are commonly seen with continuous-wave cyclophotocoagulation. Thus, this technique may become an effective alternative to standard methods of cyclophotocoagulation.

Pediatric uveitis

ABSTRACT Up to 10% of uveitis cases occur in children, with notable implications due to the risk of chronicity and vision loss. It can result from infections, autoimmune and autoinflammatory diseases, trauma, or masquerade syndromes. Primary care providers are vital in early detection, symptom management, and timely specialist referral. Depending on the etiology, symptoms may include redness, pain, photophobia, vision changes, and sometimes more severe vision loss or intense pain. Conservative initial treatment may include pain relievers and corticosteroid eye drops. Specialist care involves a thorough ocular examination and diagnostic tests to identify the underlying cause. Treatment aims to control inflammation and preserve vision, often necessitating long-term medication, with compliance being crucial. In low-resource settings, telemedicine and generic drugs may be useful to manage costs. Preventative strategies focus on prenatal care to avoid congenital infections, and distinguishing uveitis from conditions like conjunctivitis is essential for proper treatment. Multidisciplinary care ensures comprehensive management of the child’s health. In summary, early intervention and a collaborative approach among healthcare providers are key to mitigating the impact of uveitis on a child’s life.

Nailfold capillaroscopic assessment in pediatric patients with autoimmune uveitis: a case–control study

Uveitis is a major cause of visual impairment. Most uveitis cases have autoimmune etiology. Pediatric autoimmune uveitis may be associated with systemic diseases such as juvenile idiopathic arthritis or may arise as an isolated disorder. It may be accompanied by retinal vasculitis due to retinal microcirculation involvement. Nailfold capillaroscopy, a digital microscope, is a non-invasive tool for systemic microcirculation evaluation. We aimed to evaluate systemic microcirculation abnormalities in pediatric autoimmune uveitis. Twenty-five patients with pediatric autoimmune uveitis and 21 healthy children underwent detailed capillaroscopic evaluation. We assessed capillary density/mm, capillary morphology, capillary dimensions, and the presence or absence of microhemorrhages and avascular areas. The mean age of the study and control groups was 11.24 ± 3.03 and 9.9 ± 4.17 years, respectively. Most included patients had isolated uveitis and juvenile idiopathic arthritis (64% and 24%, respectively). The predominant uveitis subtype in the study was anterior uveitis (48%). A significant difference was found between cases and controls regarding mean capillary density (p-value = 0.0003) and the number of subjects having capillary density less than 7 (p-value = 0.002). Other capillaroscopic abnormalities did not show any significant difference between the studied groups. Mean capillary density did not correlate significantly with age, disease duration, or acute phase reactants. Children with autoimmune uveitis, whether isolated or as a part of systemic disease, may have systemic microcirculation involvement.Key Points• Idiopathic autoimmune uveitis is not always an isolated intraocular condition.• Systemic microcirculation involvement may occur in pediatric autoimmune uveitis, even in cases with isolated uveitis.• Nailfold capillaroscopy showed that capillary density in children with autoimmune uveitis is significantly reduced compared to healthy controls.

Biological and Therapeutic Role of Interleukin-6 in Non-Infectious Uveitis: A Narrative Review.

Biologic agents targeting interleukin-6 (IL-6) have gained attention as a promising treatment option for non-infectious uveitis (NIU) cases resistant to first-line therapies. IL-6 plays a pivotal role in the pathogenesis of uveitic conditions and its complications (i.e. macular edema and neovscularization). This review aims to assess the therapeutic potential of IL-6 inhibitors in managing NIU, especially focused in clinical outcomes, such as visual acuity and macular edema. Narrative review of studies evaluating the efficacy of IL-6 inhibitors in patients with NIU. Parameters assessed include control of inflammation, corticosteroid-sparing effects, visual acuity improvement, and reduction of macular edema. IL-6 inhibitors have demonstrated efficacy in controlling inflammation in 34% to 88% of cases and reducing corticosteroid dependence in approximately 55% of patients. Complete remission rates have been reported between 60% and 70%, with improvement in macular edema observed in 35.8% to 100% of cases. These results suggest that IL-6 inhibitors could be a therapeutic alternative for managing difficult cases of NIU. IL-6 inhibitors, including Tocilizumab and Sarilumab, have shown efficacy in controlling inflammation, improving visual outcomes, and reducing corticosteroid dependence in NIU. However, despite these promising results, further studies are needed to establish their long-term efficacy and safety. These therapies hold great potential for the future management of patients with uveitis.

Novel diagnostic method for B cell vitreoretinal lymphoma by identification of regulatory T cells and PD-1+ cytotoxic T lymphocytes in the vitreous via flow cytometry

AimsTo investigate the significance of regulatory T cells (Tregs) and programmed cell death 1 (PD-1)+ cytotoxic T lymphocytes (CTLs) in the vitreous of patients with vitreoretinal lymphoma (VRL) and uveitis.MethodsThis...

Deciphering infectious uveitis etiology: Immune cell profiling in keratic precipitates using in vivo confocal microscopy

PurposeTo elucidate the etiology of infectious uveitis through the comprehensive analysis of keratic precipitates (KPs) using in vivo confocal microscopy (IVCM). DesignCross-sectional, observational case series. MethodsThis single-center, cross-sectional study was conducted at a tertiary care eye hospital from January 2021 to October 2023. It involved a detailed ophthalmologic evaluation of all subjects and included a total of 46 eyes from 36 subjects who were diagnosed with infectious uveitis. IVCM, specifically utilizing the HRT II Rostock corneal module, was employed to study the biomicroscopic morphology of KPs. The categorization of KPs was based on cell size, morphology, and reflection. ResultsCells of KPs were assessed for size, morphology, and reflection through in vivo confocal microscopy. Patients, ranging in age from 13 to 80 years (median 51 years), exhibited diverse morphologic forms of KPs. Neutrophil-dominated KPs with uniform size were predominantly observed in bacterial and fungal endophthalmitis cases (19/19, 100 %), accompanied by small numbers of mononuclear-macrophages in three eyes (3/19, 15.8 %). Viral uveitis cases displayed a broader array of immune cell types, including characteristic striated or dendritic cells in all eyes (27/27, 100 %). Lymphocytes were commonly present (24/27, 88.9 %), forming clusters in sixteen eyes and dispersed in the corneal endothelium below the midline in eight eyes. Neutrophil infiltration was notable in three cytomegalovirus-infected eyes (3/27, 11.1 %). A marked increase in sub-basal corneal epithelial Langhans cells was associated with viral uveitis. ConclusionsNeutrophil-dominated KPs strongly indicate endogenous bacterial or fungal endophthalmitis, while the presence of dendritic cells and lymphocytes in KPs is suggestive of viral uveitis. In vivo confocal microscopy emerges as a crucial tool for differentiating the etiologic diagnosis of infectious uveitis.

Vitreoretinal Surgery in Pediatric Patients with Vitreoretinal Pathology Secondary to Uveitis

In pediatric uveitis, as with all forms of uveitis, the primary treatment modality involves achieving systemic and local immunosuppression through pharmacotherapy. However, due to the challenge of articulating symptoms by patients in the younger age group, resulting in delayed presentation to clinicians, or the tendency for uveitis to manifest more quietly in this age group, pediatric uveitis cases can be diagnosed late, unfortunately presenting with secondary complications at the time of diagnosis. In these patients, after appropriate immunosuppression is achieved, vitreoretinal surgery may be necessary to address vitreoretinal complications. Additionally, in cases where etiology cannot be determined by non-invasive methods, or when there is inadequate response or no response to treatment, rapid progression of inflammation threatening the optic nerve and macula, or suspicion of malignancy, diagnostic vitreous sampling or chorioretinal biopsy via vitreoretinal surgery may be pursued. The aim of this review is to evaluate the role and significance of vitreoretinal surgery in pediatric uveitic eyes.

Visual Impairment at Presentation in Pediatric Uveitis: A Multicentric Study in 477 Children Across Southern and Eastern India

ABSTRACT Objective To evaluate visual impairment (VI) at presentation in pediatric uveitis cases in southern and eastern India. Methods Retrospective analysis of 477 children across four tertiary centers (2015–2020). Best-documented visual acuity (ETDRS letters) in the better eye was used to categorize VI. Results Mean age at presentation was 11 ± 3.7 years; 43.8% were females, and 64.8% bilateral. Of 205 patients with complete investigations, 32.7% were undifferentiated uveitis, 31.7% infectious, 25.7% juvenile idiopathic arthritis-associated uveitis, and 10.2% other non-infectious uveitis. At presentation, 79.0% had none to mild VI, 12.6% moderate VI, and 8.4% severe VI to blindness. On generalized estimating equations analysis for individual eyes, prior oral steroids and older age were risk factors, while female gender, prior topical corticosteroids and immunosuppressive therapy were protective against moderate and/or severe VI. Conclusions Over a fifth of pediatric uveitis cases present with moderate/severe VI, especially in older age or with prior oral corticosteroid therapy.

Artificial intelligence derived large language model in decision-making process in uveitis

BackgroundUveitis is the ophthalmic subfield dealing with a broad range of intraocular inflammatory diseases. With the raising importance of LLM such as ChatGPT and their potential use in the medical field, this research explores the strengths and weaknesses of its applicability in the subfield of uveitis.MethodsA series of highly clinically relevant questions were asked three consecutive times (attempts 1, 2 and 3) of the LLM regarding current uveitis cases. The answers were classified on whether they were accurate and sufficient, partially accurate and sufficient or inaccurate and insufficient. Statistical analysis included descriptive analysis, normality distribution, non-parametric test and reliability tests. References were checked for their correctness in different medical databases.ResultsThe data showed non-normal distribution. Data between subgroups (attempts 1, 2 and 3) was comparable (Kruskal-Wallis H test, p-value = 0.7338). There was a moderate agreement between attempt 1 and attempt 2 (Cohen’s kappa, ĸ = 0.5172) as well as between attempt 2 and attempt 3 (Cohen’s kappa, ĸ = 0.4913). There was a fair agreement between attempt 1 and attempt 3 (Cohen’s kappa, ĸ = 0.3647). The average agreement was moderate (Cohen’s kappa, ĸ = 0.4577). Between the three attempts together, there was a moderate agreement (Fleiss’ kappa, ĸ = 0.4534). A total of 52 references were generated by the LLM. 22 references (42.3%) were found to be accurate and correctly cited. Another 22 references (42.3%) could not be located in any of the searched databases. The remaining 8 references (15.4%) were found to exist, but were either misinterpreted or incorrectly cited by the LLM.ConclusionOur results demonstrate the significant potential of LLMs in uveitis. However, their implementation requires rigorous training and comprehensive testing for specific medical tasks. We also found out that the references made by ChatGPT 4.o were in most cases incorrect. LLMs are likely to become invaluable tools in shaping the future of ophthalmology, enhancing clinical decision-making and patient care.

Outcomes of Micropulse Transscleral Cyclophotocoagulation in Uveitic Glaucoma.

To report a case series of patients with uveitic glaucoma who were treated with micropulse transscleral cyclophotocoagulation (mpCPC). This retrospective case series consists of patients from the University of Colorado Sue Anschutz-Rodgers Eye Center from 2015 to 2020 who were diagnosed with uveitic glaucoma. Information collected includes demographic data, type of uveitis, glaucoma severity, and prior glaucoma surgeries. Pre- and postoperative best corrected visual acuity, intraocular pressure (IOP), glaucoma medications, degree of inflammation, and uveitis therapies were included up to 36months postoperatively. Surgical success was defined as an IOP reduction of 30% with achievement of IOP goal using the same number of glaucoma medications or less at 6months or 1year. Uveitis success was defined as the absence of persistent anterior uveitis at 3months. Six patients and seven eyes with uveitic glaucoma underwent mpCPC. Types of uveitis included idiopathic anterior uveitis, HLA-B27-associated anterior uveitis, varicella zoster virus anterior uveitis, juvenile idiopathic arthritis-associated chronic anterior uveitis, lichen planus-associated intermediate uveitis, and sarcoidosis-associated panuveitis. Two of six eyes (33.3%) at 6months and three of five eyes (60%) at 1year achieved surgical success. Around 6months postoperatively, two out of seven eyes (28.6%) required Ahmed glaucoma valve placement (n = 1) or repeat mpCPC (n = 1). One eye (14.3%) required phacoemulsification with goniotomy followed by an Ahmed glaucoma valve 18months after mpCPC. There were no cases of persistent anterior uveitis, hypotony, or phthisis after mpCPC in this cohort. Micropulse transscleral cyclophotocoagulation may safely reduce intraocular pressure in some patients with uveitic glaucoma without exacerbation of intraocular inflammation. Multiple treatments may be required to achieve longer-term success.

Multiple Anterior Chamber Paracenteses May Be Needed to Identify Cytomegalovirus Anterior Uveitis

PURPOSETo demonstrate cases of anterior uveitis requiring more than one anterior chamber paracenesis to elucidate CMV as the causative etiology. DESIGNRetrospective chart review. METHODSPatients were seen at the Francis I. Proctor Foundation at the University of California, San Francisco between 2013 to 2024. Patients who required more than one anterior chamber paracentesis to detect CMV as the etiologic agent of their anterior uveitis were included. Number of anterior chamber paracenteses required to detect CMV, demographic and clinical features, viral load at time of positive anterior chamber paracentesis and association between topical corticosteroid use and viral load at time of positive anterior chamber paracentesis. RESULTSFourteen patients required a median of 2 (range 2-4) anterior chamber paracenteses to detect CMV. Mean age was 48.2 years, and 57.1% were male. Most patients (64.3%) were born in East and Southeast Asia. All affected eyes featured ocular hypertension. Five patients (35.7%) were initially treated with systemic immunosuppression before CMV was detected. Increasing frequency of topical corticosteroid use was significantly associated with higher CMV viral loads (p<0.001). Five patients (35.7%) required glaucoma surgery. In 13 patients with available data, uveitis was present for an average of 2776 days (range 23-7889 days) prior to CMV detection. Once diagnosed, most patients were treated with oral valganciclovir, with one patient transitioning to letermovir due to side effects. CONCLUSIONSCMV anterior uveitis may be more prevalent than previously recognized and often requires multiple anterior chamber paracenteses for diagnosis. Reliance on a signle negative test may lead to misdiagnosis and inappropriate treatment. Clinicians should maintain a high index of suspicion for CMV in cases of recurrent anterior uveitis, particularly in patients of East and Southeast Asian descent. This study highlights the importance of repeated testing and appropriate antiviral treatment to prevent complications such as glaucoma.

Increased serum interferon activity in sarcoidosis compared to that in tuberculosis: Implication for diagnosis?

ObjectivesIn this study, we measured serum interferon (IFN) levels and activity in patients with sarcoidosis and tuberculosis (TB) with and without uveitis. We aimed to understand the role of IFN in the pathophysiology of both conditions and explore its potential as a discriminating marker for these clinically similar diseases. MethodsSera from an Indonesian TB and a Dutch sarcoidosis cohort were used in the analysis. IFNα2 and IFNγ concentrations were measured using Simoa® and Luminex assays, respectively. Serum IFN activity was assessed by incubating THP-1 cells with patient serum and measuring IFN-stimulated gene transcription using qPCR. Anti-IFNα2 and IFNγ autoantibodies were detected via Luminex assay and tested for neutralizing capacity using a flow cytometry-based signal transducer and activator of transcription (STAT) 1 phosphorylation inhibition assay. ResultsIFNα2 was detected in 74 % and 64 % of patients with sarcoidosis and pulmonary TB, respectively, while IFNγ was found in 78 % and 23 % of patients with sarcoidosis and TB, respectively. For uveitis cases specifically, IFNα2 was detected in 85 % of sarcoid uveitis (SU) and 33 % of tubercular uveitis (TBU) cases. Similarly, IFNγ was detected in 69 % of SU and 17 % of TBU cases. IFNγ serum concentrations were higher in sarcoidosis than that in TB patients (p < 0.0001). Focusing on patients with uveitis, SU showed increased IFNα2 (p = 0.004) and IFNγ (p < 0.002) serum concentrations compared to that in TBU. Notably, TBU displayed significantly reduced IFNα2 concentrations compared to that in healthy controls (p = 0.006). These results align with the increased interferon stimulated gene (ISG) transcriptional upregulation observed in THP-1 cells stimulated with serum from patients with sarcoidosis. Elevated levels of non-neutralizing anti-IFN autoantibodies were observed in patients with TB; however, these levels were similar to those observed in geographically matched healthy Indonesian controls. ConclusionOur results suggest decreased serum levels and activity of type I and II IFN in TB compared to those in sarcoidosis. This is indicative of distinct pathophysiological processes in these highly clinically similar diseases. We propose that the assessment of serum IFN levels and IFN activity has the potential to distinguish between sarcoidosis/SU and TB/TBU.

Ocular Adverse Effects of TNF-α Inhibitors in the FDA Adverse Event Reporting System (FAERS)

Autoimmune inflammatory diseases affect 7.6-9.4% of the global population, predominantly women. TNF-α inhibitors (TNFI) have revolutionized rheumatic disease treatment but are associated with serious ocular adverse events (AEs). We analyzed FAERS data for adalimumab, etanercept, and infliximab (1998-2024), documenting patient demographics and the top 10 ocular AEs for each TNFI. Of the 45,445 reported ocular AEs, 66.6% were in females and 50.3% were in adults aged 18-64. The most common AEs included visual impairment (7,093), cataract (5,730), and blurred vision (5,586). There were 2,271 reports of blindness. The distribution of AEs was similar across adult age groups but rare in pediatric patients and those over 85. A review by da Silva et al corroborates our findings, identifying uveitis, optic neuropathy, and retinal toxicity among others. FAERS data showed 1,927 uveitis cases linked to adalimumab, 1,054 to etanercept, and 1,076 to infliximab. These AEs may result from TNF-α binding in ocular tissues, paradoxically causing and treating uveitis. Our study highlights the severity of ocular AEs with TNFI use, suggesting a need for vigilance in monitoring patients, especially given the potential for irreversible blindness. The limitations include voluntary reporting and underreporting in FAERS, underscoring the need for further research to better understand these risks.

Intermediate uveitis in common variable immunodeficiency (CVID) associated with a heterozygous variant in the TNFRSF13B gene.

To report on a rare case of intermediate uveitis occurring in a patient with common variable immunodeficiency (CVID) and a heterozygous TNFRSF13B variant. Observational case report. A 23-year-old male presented with a 3-month history of increasing floaters and blurred vision to both eyes. He had been treated with topical and intravitreal corticosteroids by his local ophthalmologist nine months before. Ocular examination demonstrated bilateral intermediate uveitis with retinal vasculitis. He had been treated with intravenous immunoglobulins during childhood, due to primary humoral immunodeficiency. Systemic work-up for other causes of intermediate uveitis was unremarkable, notably no features of systemic sarcoid-like disease were detected. Initial treatment with mycophenolate mofetil showed insufficient response, and upon switching to adalimumab, clinical remission was achieved. Immunocytometry and genetic work-up revealed a smB+CD21norm subtype of CVID and a heterozygous TNFRSF13B variant. This report of CVID-associated intermediate uveitis in a patient with a heterozygous TNFRSF13B variant highlights the potential involvement of the eye within CVID-associated autoimmunity and the role for anti-TNF blockade in this challenging group of patients.

Paediatric Uveitis - the uniqueness in clinical presentation and the efficacy of biologics treatment

AimsTo evaluate unique clinical characteristics of paediatric uveitis in our locality and treatment outcomes especially the efficacy of biologics.MethodsThis was a retrospective cohort.Results37 paediatric uveitis cases involving 67 eyes were included. Male-to-female ratio was 1:1.3. Mean age of uveitis onset was 11 ± 3.7 (4–18). 81.1% cases suffered from bilateral uveitis. 75.7% cases were chronic uveitis. Nearly half of the cases (40.5%) presented with anterior uveitis. The predominant diagnosis of uveitis in our cohort was idiopathic. Unlike studies from other populations, the associated systemic conditions in this mostly Chinese cohort were Behçet’s disease (8.1%), tubulointerstitial nephritis and uveitis (8.1%) and HLA-B27 associated uveitis (8.1%). Steroid response was a common phenomenon, observed in 40.5% of cases. The most common complication was posterior synechiae (45.9%), followed by cataract (37.8%), glaucoma (27.0%), band keratopathy (18.9%) and macular oedema (13.5%). 3/37 patients encountered either first attack of uveitis or flare after receiving COVID-19 vaccine. 54.1% of patients required systemic steroid for disease control. The majority required steroid sparing immunotherapy, including Methotrexate (43.2%), Mycophenolate Mofetil (24.3%), Cyclosporine A (8.1%), Azathioprine (5.4%) and Tacrolimus (2.7%). Resistant cases required biologics including tumour necrosis factor alpha inhibitors (Adalimumab 32.4%, Infliximab 2.7%) and interleukin-6 inhibitors (Tocilizumab 2.7%).ConclusionsClinical presentation of the local paediatric uveitis differs from previously described features in Caucasian and other populations. According to our experience as a tertiary eye centre, Behçet’s disease, tubulointerstitial nephritis and uveitis and HLA-B27 associated uveitis were more often encountered than Juvenile Idiopathic Arthritis associated uveitis. Our report evaluated the efficacy of immunomodulatory therapy and biologics in controlling uveitis and reducing ocular complications.

A Rare Case of Bilateral Anterior Uveitis Revealing Ocular Toxocarosis

We present a rare case of bilateral anterior uveitis in a 10-year-old patient, which revealed ocular toxocariasis. The patient complained of blurred vision and bilateral eye pain, and clinical examination showed the presence of synechia and incipient cataract. Serological tests confirmed that the patient was indeed infected with Toxocara. Treatment with local corticosteroids and anthelmintics resulted in significant improvement, highlighting the significance of considering toxocariasis in similar cases.

Рифабутин-индуцированный увеит при коинфекции вич/туберкулез. Клинический случай

Purpose. To present a case of rifabutin-induced uveitis in a patient with HIV/tuberculosis coinfection. Clinical case. We observed a patient with HIV-associated tuberculosis and drug-induced uveitis of both eyes in May 2023. He received a treatment regimen that included Rifabutin and noted redness of both eyes, pain, photophobia, lacrimation, and decreased visual acuity after 2 months from the start of treatment. A standard ophthalmic examination was carried out. Rifabutin was discontinued and corticosteroids and mydriatics were prescribed considering the patient’s HIV status and clinical signs. Against the background of the therapy, persistent positive dynamics was noted. Key words: rifabutin; drug-induced uveitis; HIV; tuberculosis.

Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy.

Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57-secukinumab (SEC), 22-netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065-0.107), during IL17-i therapy- 9.2 per 100 pt-years (95% CI 0.06-0.15), p = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079-0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), p = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028-0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019-022), p= 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18-0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18-0.43), p = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.